Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
0.8200
Nov 20 • 3:59 PM ET Dollar change-0.1353 Percentage change(-14.16%)
Aftermarket Close
0.8199
Aftermarket • 7:30 PM ET Dollar change-0.0001 Percentage change(-0.01%)
Index
-
Market Cap
10.88M
Enterprise Value
38.89M
Income
-74.20M
Sales
0.00M
Book/sh
-1.00
Cash/sh
2.38
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
100
IPO
Feb 02, 2024
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
0.35
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
1.98
Current Ratio
1.98
Debt/Eq
-
LT Debt/Eq
-
Option/Short
No / Yes
EPS (ttm)
-5.72
EPS next Y
-4.83
EPS next Q
-1.01
EPS this Y
82.66%
EPS next Y
-24.68%
EPS next 5Y
44.05%
EPS past 3/5Y
-11.62% -16.69%
Sales past 3/5Y
- -
EPS Y/Y TTM
79.01%
Sales Y/Y TTM
-100.00%
EPS Q/Q
87.38%
Sales Q/Q
-
Insider Own
15.01%
Insider Trans
13.44%
Inst Own
36.94%
Inst Trans
-3.69%
ROA
-82.35%
ROE
-778.33%
ROIC
-182.37%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-11.66%
SMA50
-74.34%
SMA200
-87.76%
Trades
Shs Outstand
13.27M
Shs Float
11.27M
52W High
29.34 -97.21%
52W Low
0.80 2.49%
Volatility
16.43% 12.97%
ATR (14)
0.21
RSI (14)
26.87
Beta
2.52
Rel Volume
0.68
Avg Volume
497.61K
Volume
337,183
Perf Week
-9.25%
Perf Month
-27.43%
Perf Quarter
-90.89%
Perf Half Y
-92.49%
Perf YTD
-96.89%
Perf Year
-94.70%
Perf 3Y
-
Perf 5Y
-
Perf 10Y
-
Prev Close
0.96
Price
0.82
Change %
-14.16%
Consensus
Strong Buy
Avg. Price Target
$23.80
Implied Upside
+2,802.4%
Analysts5incl. previous ratings
Rating Distribution4 Buy · 1 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jan 30, 2026Downgrade
MS logoMMorgan Stanley
Overweight → Equal-Weight$2+143.9%
Sep 15, 2025Initiated
HH.C. Wainwright
Buy$9+997.6%
Aug 28, 2025Initiated
LLadenburg Thalmann
Buy$3.60+339.0%
Feb 28, 2024Initiated
EVR logoEEvercore ISI
Outperform
Feb 27, 2024Initiated
MS logoMMorgan Stanley
Overweight$18+2,095.1%
Feb 27, 2024Initiated
BAC logoBBofA Securities
Buy$26+3,070.7%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BRADLEY WILLIAMDirectorSep 14 '26Buy0.6264,51639,903149,138Sep 16 04:05 PM
Royan AjayDirectorJun 12 '26Buy0.8523,00019,59640,901Jun 15 06:06 PM
BRADLEY WILLIAMDirectorJun 10 '26Buy0.7368,49350,32984,622Jun 11 05:04 PM
Sheffield IanDirectorJun 10 '26Buy0.7335,00025,52935,000Jun 11 05:00 PM
Rajagopalan HarithChief Executive OfficerJun 10 '26Buy0.7325,00018,252540,557Jun 11 04:59 PM
Smith Weber LaraChief Financial OfficerJun 08 '26Buy0.6920,00013,70820,000Jun 09 06:55 PM
Rajagopalan HarithChief Executive OfficerDec 04 '25Buy1.9210,41619,999501,745Dec 08 07:05 AM
Fractyl Health, Inc. is a metabolic therapeutics company. It develops medical device solutions for the treatment of metabolic diseases, which includes type 2 diabetes and obesity. The company was founded by Harith Rajagopalan and Jay D. Caplan on August 30, 2010 and is headquartered in Burlington, MA.
Ph.D.Dr. Harith Rajagopalan M.D.
General Counsel & Corporate SecretaryMs. Sarah S. Toomey Esq.
CFO & TreasurerMs. Lara Smith Weber
Head of Investor Relations & Corporate DevelopmentMr. Brian Luque
Senior Vice President of RegulatoryMr. Jon Fitzgerald